Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

immunomodulatory genes. In: Boiron
M, Marty M, eds. Eurocancer 96. Paris:
John Libbey 1996.
41 Pardoll DM. Paracrine cytokine adjuvants
in cancer immunotherapy. Annu
Rev Immunol 1995; 13: 399±415.
42 Colombo MP, Forni G. Immunotherapy:
cytokine gene transfer strategies.
Cancer Metastasis Rev 1996; 15: 317±328.
43 Hellstrom KE, Hellstrom I, Chen L.
Can co-stimulated tumor immunity be
therapeutically efficacious? Immunol
Rev 1995; 145: 123±145.
44 Huang AYC, Bruce AT, Pardoll DM,
Levitsky HI. Does B7±1 expression
confer antigen-presenting cell capacity
to tumors in vivo? J Exp Med 1996; 183:
769±776.
45 Schirrmacher V, Haas C, Bonifer R,
Ahlert T, Gerhards R, Ertel C. Human
tumor cell modification by virus
infection: an efficient and safe way to
produce cancer vaccine with pleiotropic
immune stimulatory properties when
using Newcastle disease virus. Gene
Ther 1999; 6: 63±73.
46 Nabel GJ, Chang A, Nabel EG,
Plautz G, Fox BA, Huang L, Shu S.
Clinical protocol: immunotherapy of
malignancy by in vivo gene transfer into
tumors. Hum Gene Ther 1992; 3: 399±
410.
47 Fabre JW. The allogeneic response and
tumor immunity. Nat Med 2001; 7:
649±652.
48 Melcher AA, Todryk S, Hardwick N,
Ford M, Jacobson M,Vile RG. Tumor
immunogenicity is determined by the
mechanism of cell death via induction
of heat shock protein expression. Nat
Med 1998; 4: 581±587.
49 Srivastava PK, Menoret A, Basu S,
Binder RJ, McQuade KL. Heat shock
proteins come of age: primitive functions
acquire new roles in an adaptive
world. Immunity 1998; 8: 657±665.
50 Banchereau J, Palucka AK, Dhodapkar
M, Burkeholder S, Taquet N,
Rolland A, Taquet S, Coquery S,
Wittkowski KM, Bhardwaj N, Pineiro
L, Steinman R, Fay J. Immune and
clinical responses in patients with metastatic
melanoma to CD34 + progenitor-
References
derived dendritic cell vaccine. Cancer
Res 2001; 61: 6451±6458.
51 Nestle FO, Banchereau J, Hart D.
Dendritic cells: on the move from the
bench to the bedside. Nat Med 2001; 7:
761±765.
52 Melero I,Vile RG, Colombo MP.
Feeding dendritic cells with tumor antigens:
self-service buffet or a la carte?
Gene Ther 2000; 7: 1167±1170.
53 Albert ML, Sauter B, Bhardwaj N.
Dendritic cells acquire antigen from
apoptotic cells and induce class I-restricted
CTLs. Nature 1998; 392: 86±89.
54 Dalgleish A. The case for therapeutic
vaccines. Melanoma Res 1996; 6: 5±10.
55 Hock H, Dorsch M, Kunzendorf U,
Uberla K, Qin Z, Diamanstein T,
Blankenstein T. Vaccinations with tumor
cells genetically engineered to produce
different cytokines: effectivity not
superior to a classical adjuvant. Cancer
Res 1993; 53: 714±716.
56 Singh M, O'Hagan D. Advances in
vaccine adjuvants. Nat Biotechnol 1999;
17: 1075±1081.
57 Forni G, Lollini PL, Musiani P, Colombo
MP. Immunoprevention of cancer:
is the time ripe? Cancer Res 2000;
60: 2571±2575.
58 Wilson JM. Perspective series: molecular
medicine in genetically engineered
animals. J Clin Invest 1996; 97: 1138±
1141.
59 Di Carlo E, Forni G, Lollini P, Colombo
MP, Modesti A, Musiani P.
The intriguing role of polymorphonuclear
neutrophils in antitumor reactions.
Blood 2001; 97: 339±345.
60 Gough MJ, Melcher AA, Ahmed A,
Crittenden MR, Riddle DS, Linardakis
E, Ruchatz AN,Vile RG. Macrophages
orchestrate the immune response
to tumor cell death. Cancer Res
2001; 61: 7240±7247.
61 Sauter B, Albert ML, Francisco L,
Larsson M, Somersan S, Bhardwaj N.
Consequences of cell death: exposure to
necrotic tumor cells, but not primary
tissue cells or apoptotic cells, induces
the maturation of immunostimulatory
dendritic cells. J Exp Med 2000; 191:
423±434.
227